Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): preliminary report

• Published in: Journal of experimental pathology Vol. 3; no. 4; p. 705
• Main Authors: Costigliola, P, Ricchi, E, Colangeli, V, Pintori, C, Boni, P, Chiodo, F
• Format: Journal Article
• Language: English
• Published: United States 1987
• Subjects: Adjuvants, Immunologic - therapeutic use; AIDS-Related Complex - therapy; Humans; Leukocyte Count; Lymphocytes - immunology; Peptide Fragments - therapeutic use; Thymopentin; Thymopoietins - therapeutic use; Thymus Hormones - therapeutic use
• ISSN: 0730-8485

Persistent generalized lymphadenopathy during HIV infection is now a well classified syndrome featuring multiple chronic lymph node enlargement frequently associated with further symptoms (diarrhea, nocturnal sweating, loss of weight, fever): it is invariably accompanied by serious alterations of the cell-mediated immunity including lymphopenia, reduced number of helper lymphocytes in circulation, inversion of the helper/suppressor ratio, lower proliferative response in vitro and deficient delayed skin sensitivity tests. Minor opportunistic infections are also more frequent, the most widespread being chronic oral candidiasis. Whenever several of these signs are associated in a single patient, especially if the immunitary deficit is severe, an immunomodulating treatment is indicated to improve the lymphocyte functionality and finally to modify any evolutive tendency. The Authors give the preliminary results of a pilot study carried out on 12 patients with LAS/ARC treated with Thymopentin at a dosage of 50 mg by intra muscular injection on alternate days for cycles of 30 days. Compared with 14 untreated patients, the subjects receiving therapy showed a more stable immunological picture, and improvement in subjective symptoms and a better therapeutic response to minor opportunistic infections.